Chiltern (Early Phase) Limited
About Chiltern
CHILTERN (EARLY PHASE) LTD, PART OF CHILTERN GROUP, IS A HOSPITAL-BASED CLINICAL PHARMACOLOGY UNIT SPECIALISING IN FIRST-IN-MAN AND DRUG PHOTOTOXICITY STUDIES
Company Description and Services
Chiltern (Early Phase) Ltd., (CEP), specialises in Phase I clinical trials, especially in New Chemical Entities and Phototoxicity studies. During the past 25 years, CEP has performed over 700 research studies for the international pharmaceutical and biotechnology industry, covering a wide range of pharmacokinetic and pharmacodynamic studies in all the major therapeutic areas. We also offer single and multiple dose study programmes, drug-drug interaction studies, bioequivalence and bioavailability studies and studies investigating the effects of age, gender and food on drug kinetics.
Facilities
The company has a 42 bed clinical unit located on the site of Ninewells Hospital - one of the largest hospital complexes in Europe.
- Focus : Service
- Industry : Pharma
